Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 49, 2019 - Issue 7
Submit an article Journal homepage
121
Views
0
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Model-based pharmacokinetic and pharmacodynamic analysis for acute effects of a small molecule inhibitor of diacylglycerol acyltransferase-1 in the TallyHo/JngJ polygenic mouse

Yoon-Jee ChaeCKD Research Institute, Gyeonggi-do, Republic of Korea; View further author information
,
Jin Sook SongBio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea; View further author information
,
Jin Hee AhnDepartment of Chemistry, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea; View further author information
,
Myung Ae BaeBio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea; ;Department of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon, Republic of Korea; View further author information
&
Kyeong-Ryoon LeeLaboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Chungbuk, Republic of KoreaCorrespondence[email protected]
View further author information
Pages 823-832 | Received 08 May 2018, Accepted 29 Jun 2018, Published online: 05 Sep 2018

References

  • Buhman KK, Smith SJ, Stone SJ, et al. (2002). DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 277:25474–9.
  • Cao J, Zhou Y, Peng H, et al. (2011). Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem 286:41838–51.
  • Cases S, Smith SJ, Zheng Y-W, et al. (1998). Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci 95:13018–23.
  • Cases S, Stone SJ, Zhou P, et al. (2001). Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 276:38870–6.
  • Dayneka NL, Garg V, Jusko WJ. (1993). Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457–78.
  • Dow RL, Li J-C, Pence MP, et al. (2011). Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1. ACS Med Chem Lett 2:407–12.
  • Eliot LA, Foster RT, Jamali F. (1999). Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 16:309–13.
  • Enayetallah AE, Ziemek D, Leininger MT, et al. (2011). Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. PLoS One 6:e27009.
  • Faltaos DW, Urien S, Carreau V, et al. (2006). Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol 20:321–30.
  • Farnier M, Davignon J. (1998). Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82:3J–10J.
  • Gibbons G, Wiggins D, Brown A-M, Hebbachi A-M. 2004. Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc T 32:59–64.
  • Kim JH, Sen Ś, Avery CS, et al. (2001). Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics 74:273–86.
  • Kim JH, Stewart TP, Soltani-Bejnood M, et al. (2006). Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J Endocrinol 191:437–46.
  • Kim JH, Stewart TP, Zhang W, et al. (2005). Type 2 diabetes mouse model TallyHo carries an obesity gene on chromosome 6 that exaggerates dietary obesity. Physiol Genom 22:171–81.
  • King AJ, Segreti JA, Larson KJ, et al. (2009). Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. J Pharmacol Exp Ther 330:526–31.
  • Maron DJ, Fazio S, Linton MF. (2000). Current perspectives on statins. Circulation 101:207–13.
  • Meyers CD, Kamanna VS, Kashyap ML. (2004). Niacin therapy in atherosclerosis. Curr Opin Lipidol 15:659–65.
  • Michaelis UR, Xia N, Barbosa-Sicard E, et al. (2008). Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells. Invest Ophthalmol Vis Sci 49:1242–7.
  • Rhee SD, Jeong WH, Sung YY, et al. (2004). Characteristics of the newly established diabetic model mice, TallyHo. J Korean Diabetes Assoc 28:177–86.
  • Ross R, Harker L. (1976). Hyperlipidemia and atherosclerosis. Science 193:1094–100.
  • Shayeganpour A, Jun AS, Brocks DR. (2005). Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26:249–57.
  • Snow V, Aronson MD, Hornbake ER, et al. (2004). Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 140:644–9.
  • Streeper RS, Koliwad SK, Villanueva CJ, Farese RV. (2006). Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. Am J Physiol-Endocrinol Metabol 291:E388–E94.
  • Subauste A, Burant CF. (2003). DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord 3:263–70.
  • Van Schaick EA, De Greef HJ, Ijzerman AP, Danhof M. (1997). Physiological indirect effect modeling of the antilipolytic effects of adenosine A 1-receptor agonists. J Pharmacokinet Biopharm 25:673–94.
  • Wojcicki J, Gornik W, Pawlik A, et al. (1996). Comparative pharmacokinetics of theophylline in rabbits and in humans with hyperlipidemia. Pulmon Pharmacol 9:175–8.
  • Zhang Y, Ren J. (2011). Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy. Hypertension 57:148–50.
  • Zhao G, Souers AJ, Voorbach M, et al. (2008). Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 51:380.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.